AzTrials
AzTrials

Small Cell Lung CancerPhase 2SEZanneNCT07155174

A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

A Phase 2 study testing ABBV-706, Atezolizumab and Etoposide in people with Small Cell Lung Cancer, run by AbbVie at 70 sites in 13 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Small Cell Lung Cancer
What is being tested?
ABBV-706, Atezolizumab and Etoposide
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
180 participants
Where
70 sitesin 13 countries
Study dates
25 Nov 2025to Sep 2031
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Diagnosis of histologically or cytologically confirmed extensive stage small cell lung cancer (ES-SCLC) requiring treatment with first line therapy.
  • Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1 during the screening period prior to the first dose of study treatment.
  • Have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST v1.1).
  • Suspected brain metastases at screening should have a computed tomography (CT)/ magnetic resonance imaging (MRI) of the brain prior to study entry.

Who cannot join

  • Have received any kind of treatment for limited stage small cell lung cancer (LS-SCLC).
  • Known active/symptomatic central nervous system (CNS) metastases should be excluded.
  • History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, or any evidence of active ILD/pneumonitis on screening chest computed tomography (CT) scan should be excluded.
  • Have any clinically significant conditions that would adversely affect the participant's participation in the study, and the subject should have a life expectancy of at least 3 months.

Trial locations and contacts

70 sites in 13 countries. Contact the study team or a site near you to ask about taking part.

ABBVIE CALL CENTER contact

844-663-3742

abbvieclinicaltrials@abbvie.com

70 sites in 13 countries

United States12 sites, 12 recruiting

  • Dana-Farber Cancer Institute /ID# 277732

    Boston, Massachusetts, 02215

    Recruiting

  • University Hospitals Cleveland Medical Center /ID# 277556

    Cleveland, Ohio, 44106

    Recruiting

  • Missouri Cancer Associates /ID# 278299

    Columbia, Missouri, 65201

    Recruiting

  • Henry Ford Hospital - Detroit /ID# 277218

    Detroit, Michigan, 48202

    Recruiting

  • Virginia Cancer Specialists - Fairfax /ID# 278298

    Fairfax, Virginia, 22031

    Recruiting

  • Fort Wayne Medical Oncology And Hematology /ID# 277336

    Fort Wayne, Indiana, 46804

    Recruiting

  • University of Florida College of Medicine /ID# 277496

    Gainesville, Florida, 32610

    Recruiting

  • The University of Texas MD Anderson Cancer Center /ID# 277929

    Houston, Texas, 77030

    Recruiting

  • Baptist Health Lexington /ID# 277729

    Lexington, Kentucky, 40503

    Recruiting

  • Yale University School of Medicine /ID# 278181

    New Haven, Connecticut, 06510

    Recruiting

  • Ocala Oncology Center /ID# 278269

    Ocala, Florida, 34474

    Recruiting

  • Moffitt Cancer Center /ID# 277573

    Tampa, Florida, 33612

    Recruiting

Other trials in United States

China7 sites, 7 recruiting

  • Cancer Hospital - Chinese Academy of Medical Sciences /ID# 277167

    Beijing, Beijing Municipality, 100021

    Recruiting

  • West China Hospital of Sichuan University /ID# 277852

    Chengdu, Sichuan, 610041

    Recruiting

  • The First affiliated hospital of Nanchang University /ID# 277247

    Nanchang, Jiangxi, 330006

    Recruiting

  • Shanghai East Hospital /ID# 277111

    Shanghai, Shanghai Municipality, 200120

    Recruiting

  • Shanghai Pulmonary Hospital /ID# 276960

    Shanghai, Shanghai Municipality, 200433

    Recruiting

  • Union Hospital Tongji Medical College /ID# 277912

    Wuhan, Hubei, 430048

    Recruiting

  • Henan Cancer Hospital /ID# 277059

    Zhengzhou, Henan, 450008

    Recruiting

Other trials in China

South Korea6 sites, 6 recruiting

  • Chungbuk National University Hospital /ID# 277429

    Cheongju-si, North Chungcheong, 28644

    Recruiting

  • National Cancer Center /ID# 277434

    Goyang-si, Gyeonggido, 10408

    Recruiting

  • Seoul National University Hospital /ID# 277271

    Seoul, Seoul Teugbyeolsi, 03080

    Recruiting

  • Yonsei University Health System - Severance Hospital /ID# 277597

    Seoul, Seoul Teugbyeolsi, 03722

    Recruiting

  • Asan Medical Center /ID# 277603

    Seoul, Seoul Teugbyeolsi, 05505

    Recruiting

  • Samsung Medical Center /ID# 277615

    Seoul, Seoul Teugbyeolsi, 06351

    Recruiting

Other trials in South Korea

Turkey (Türkiye)6 sites, 6 recruiting

  • Adana Sehir Hastanesi /ID# 277082

    Adana, 01370

    Recruiting

  • Memorial Ankara Hastanesi /ID# 276840

    Ankara, 06520

    Recruiting

  • Gazi University Medical Faculty /ID# 276843

    Ankara, 06560

    Recruiting

  • Ankara Universitesi Tip Fakultesi Cebeci Hastanesi /ID# 277076

    Ankara, 06620

    Recruiting

  • Liv Hospital Ankara /ID# 276842

    Ankara, 06680

    Recruiting

  • Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi /ID# 276839

    Istanbul, 34722

    Recruiting

Other trials in Turkey (Türkiye)

Israel5 sites, 5 recruiting

  • Assuta Ashdod Medical Center /ID# 276661

    Ashdod, Southern District, 7747600

    Recruiting

  • Rambam Health Care Campus- Haifa /ID# 276663

    Haifa, 3109601

    Recruiting

  • Hadassah Medical Center-Hebrew University /ID# 276662

    Jerusalem, 91120

    Recruiting

  • Meir Medical Center /ID# 277292

    Kefar Sava, Central District, 4428164

    Recruiting

  • The Chaim Sheba Medical Center /ID# 276660

    Ramat Gan, Tel Aviv, 5265601

    Recruiting

Other trials in Israel

Japan5 sites, 5 recruiting

  • Tokyo Metropolitan Komagome Hospital /ID# 277335

    Bunkyo Ku, Tokyo, 113-8677

    Recruiting

  • National Cancer Center Hospital /ID# 277237

    Chuo-Ku, Tokyo, 104-0045

    Recruiting

  • National Cancer Center Hospital East /ID# 277239

    Kashiwa-shi, Chiba, 277-8577

    Recruiting

  • Shizuoka Cancer Center /ID# 277243

    Sunto-gun, Shizuoka, 411-8777

    Recruiting

  • Wakayama Medical University Hospital /ID# 277260

    Wakayama, Wakayama, 641-8510

    Recruiting

Other trials in Japan

Serbia5 sites, 5 recruiting

  • University Clinical Center Serbia /ID# 277007

    Belgrade, Beograd, 11000

    Recruiting

  • Clinical Hospital Center - Bezanijska Kosa /ID# 277013

    Belgrade, Beograd, 11080

    Recruiting

  • Institute For Pulmonary Diseases Of Vojvodina /ID# 277003

    Kamenitz, Sremski Okrug, 21208

    Recruiting

  • University Clinical Center Kragujevac /ID# 277179

    Kragujevac, Sumadijski Okrug, 34000

    Recruiting

  • University Clinical Center Nis /ID# 277180

    Niš, Nisavski Okrug, 18300

    Recruiting

Other trials in Serbia

Spain5 sites, 5 recruiting

  • Complejo Hospitalario Universitario A Coruna /ID# 276922

    A Coruña, 15006

    Recruiting

  • Hospital Clinic de Barcelona /ID# 276878

    Barcelona, 08036

    Recruiting

  • Hospital General Universitario Gregorio Maranon /ID# 276877

    Madrid, 28007

    Recruiting

  • Hospital Universitario 12 de Octubre /ID# 277251

    Madrid, 28041

    Recruiting

  • Hospital Regional Universitario de Malaga /ID# 276927

    Málaga, Andalusia, 29010

    Recruiting

Other trials in Spain

Taiwan5 sites, 5 recruiting

  • Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 277267

    Kaohsiung City, 807

    Recruiting

  • Kaohsiung Chang Gung Memorial Hospital /ID# 277725

    Kaohsiung City, 833

    Recruiting

  • Chung Shan Medical University Hospital /ID# 277660

    Taichung, 402

    Recruiting

  • Taipei Veterans General Hospital /ID# 277263

    Taipei, 112

    Recruiting

  • Linkou Chang Gung Memorial Hospital /ID# 277264

    Taoyuan City, 333

    Recruiting

Other trials in Taiwan

Belgium4 sites, 4 recruiting

  • Grand Hopital de Charleroi - Les Viviers /ID# 276897

    Charleroi, Hainaut, 6280

    Recruiting

  • AZ Maria Middelares /ID# 277027

    Ghent, Oost-Vlaanderen, 9000

    Recruiting

  • Jessa Ziekenhuis - Campus Virga Jesse /ID# 276781

    Hasselt, Limburg, 3500

    Recruiting

  • Groupe Sante CHC - Clinique du MontLegia /ID# 276783

    Liège, 4000

    Recruiting

Other trials in Belgium

Italy4 sites, 4 recruiting

  • IRCCS Ospedale San Raffaele /ID# 276793

    Milan, Milano, 20132

    Recruiting

  • Azienda Ospedaliero Universitaria San Luigi Gonzaga /ID# 276789

    Orbassano, Torino, 10043

    Recruiting

  • Fondazione Policlinico Universitario Campus Bio-Medico /ID# 277744

    Roma, 00128

    Recruiting

  • IRCCS Istituti Fisioterapici Ospitalieri-Istituto Nazionale Tumori Regina Elena /ID# 276792

    Rome, Roma, 00144

    Recruiting

Other trials in Italy

Germany3 sites, 3 recruiting

  • Evangelische Lungenklinik Berlin /ID# 277094

    Berlin, 13125

    Recruiting

  • Lungenfachklinik Immenhausen /ID# 278005

    Immenhausen, Hesse, 34376

    Site Coordinator, +49 5673 5011573

    Recruiting

  • Universitaetsklinikum Giessen und Marburg GmbH /ID# 277466

    Marburg, Hesse, 35043

    Site Coordinator, +49 641 985 43501, oon.studienzentrum@uk-gm.de

    Recruiting

Other trials in Germany

Poland3 sites, 3 recruiting

  • Uniwersytecki Szpital Kliniczny Nr 4 w Lublinie /ID# 276910

    Lublin, Lublin Voivodeship, 20-090

    Recruiting

  • Wielkopolskie Centrum Pulmonologii i Torakochirurgii im. Eugenii i Janusza Zeyla /ID# 276907

    Poznan, Greater Poland Voivodeship, 60-569

    Recruiting

  • Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Bada /ID# 277112

    Warsaw, Masovian Voivodeship, 02-781

    Recruiting

Other trials in Poland

About this study

Official title: A Phase 2 Randomized, Open Label, Multicenter Study to Evaluate the Optimal Dose, Safety, and Efficacy of ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Subjects With Previously Untreated Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain. The purpose of this study is to assess safety, dose, change in disease activity of ABBV-706 given with atezolizumab, compared to standard of care (SOC) treatment (etoposide, carboplatin, atezolizumab, and optional lurbinectedin).

ABBV-706 is an investigational drug being developed for the treatment of SCLC. There are multiple treatment arms in this study. Participants will either receive ABBV-706 given with atezolizumab, at 1 of 2 doses, or SOC. Approximately 180 adult participants will be enrolled in the study across sites worldwide.

Read more

In the safety lead-in, participants with SCLC will receive intravenous (IV) ABBV-706 in 1 of 2 doses with IV atezolizumab, or IV SOC. In the expansion portion of the study, participants with SCLC will receive IV ABBV-706 in 1 of 2 doses with atezolizumab, or IV SOC, until the optimal dose of ABBV-706 is determined. The estimated duration of the study is up to 69.5 months.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, questionnaires, and scans.

Being tested
ABBV-706, Atezolizumab, Etoposide, Carboplatin, Lurbinectedin
Keywords
Small Cell Lung Cancer, SCLC, ABBV-706, Etoposide, Carboplatin, Atezolizumab, Lurbinectedin
Medical subject headings
Small Cell Lung Carcinoma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07155174
Study groupRoleWhat they receive
Safety Lead-In: ABBV-706 Dose AExperimentalParticipants will receive ABBV-706 dose A in combination with atezolizumab, as part of the approximately 69.5 month study duration.
Receives: Drug: ABBV-706; Drug: Atezolizumab
Safety Lead-In: ABBV-706 Dose BExperimentalParticipants will receive ABBV-706 dose B in combination with atezolizumab, as part of the approximately 69.5 month study duration.
Receives: Drug: ABBV-706; Drug: Atezolizumab
Safety Lead-In: Stand of Care (SOC)ExperimentalParticipants will receive SOC (etoposide, carboplatin, atezolizumab, and optional lurbinectedin), as part of the approximately 69.5 month study duration.
Receives: Drug: Atezolizumab; Drug: Etoposide; Drug: Carboplatin; Drug: Lurbinectedin
Expansion: ABBV-706 Dose AExperimentalParticipants will receive ABBV-706 dose A in combination with atezolizumab, as part of the approximately 69.5 month study duration.
Receives: Drug: ABBV-706; Drug: Atezolizumab
Expansion: ABBV-706 Dose BExperimentalParticipants will receive ABBV-706 dose B in combination with atezolizumab, as part of the approximately 69.5 month study duration.
Receives: Drug: ABBV-706; Drug: Atezolizumab
Expansion: SOCExperimentalParticipants will receive SOC (etoposide, carboplatin, atezolizumab, and optional lurbinectedin), as part of the approximately 69.5 month study duration.
Receives: Drug: Atezolizumab; Drug: Etoposide; Drug: Carboplatin; Drug: Lurbinectedin

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants with Adverse Events (AE)s

    An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

    Measured: Up to 69.5 Months

  2. Progression-Free Survival (PFS) Based on Investigator Assessment

    PFS is defined as the time from randomization to the first documentation of radiological progressive disease (PD) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 per investigator or death from any cause, whichever occurs first.

    Measured: Up to Approximately 24 Months

Secondary outcomes (4)

  1. Overall Response (OR) as Measured by Overall Response Rate (ORR) Based on Investigator Assessment

    OR is defined as participants achieving a best overall response (BOR) of confirmed complete response (CR)/partial response (PR) per RECIST v1.1 as determined by investigator prior to initiation of subsequent anti-cancer therapy. OR will be summarized by ORR, defined as the proportion of subjects achieving OR and will be summarized for each arm with its associated 95% confidence interval (CI).

    Measured: Up to Approximately 24 Months

  2. Duration of Response (DoR) Based on Investigator Assessment

    DoR is defined as time from the initial response of CR/PR until the first documentation of radiographical PD according to RECIST v1.1 by investigator or death from any cause, whichever occurs first.

    Measured: Up to Approximately 24 Months

  3. Disease Control (DC) Based on Investigator Assessment

    DC is defined as achieving an OR or stable disease (SD) according to RECIST v1.1 by investigator at any time prior to subsequent anti-cancer therapy.

    Measured: Up to Approximately 24 Months

  4. OS

    OS, is defined as the time from randomization to death from any cause.

    Measured: Up to Approximately 28 Months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Sep 2025
  2. Study start25 Nov 2025
  3. Primary completionApr 2029 (estimated)
  4. Study completionSep 2031 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Sequential
Masking
None (open label)
Enrolment
180 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07155174
Sponsor's protocol ID
M24-633
Other IDs
2024-517490-24
Acronym
SEZanne
Status last verified
Oct 2026
First submitted
28 Aug 2025
Last updated
27 Oct 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing ABBV-706, Atezolizumab and Etoposide in people with Small Cell Lung Cancer, run by AbbVie at 70 sites in 13 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 27 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 70 sites in United States, China, South Korea, Turkey (Türkiye), Israel and 8 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact ABBVIE CALL CENTER (844-663-3742, abbvieclinicaltrials@abbvie.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants with Adverse Events (AE)s (time frame: Up to 69.5 Months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07155174.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Oct 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in